Phase II trials for an experimental drug LY573636 are about to commence. The primary objective is to estimate the time to progressive disease for patients who receive LY573636 after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. CT-scans will be done before the first dose and then after every other treatment.
HOW DOES THIS COMPOUND WORK?
LY573636 is a cytotoxic agent that appears to possess a unique mechanism of
action by inducing apoptosis [programmed cell death] in a variety of human tumor cell lines. It also appears to inhibit the proliferation of VEGF-stimulated endothelial cells [vascular endothelial growth factor-tells cells to grow] and it promotes tumor cell cycle arrest [tells tumor cells to stop dividing].
Demonstrates in vivo efficacy in colorectal xenograft [transplant] models.
Eli Lilly Trades on the NYSE under the symbol LLY. It closed friday down 20 cents to 57.56 in below average trading. Most of the major pharma companies were down however. I will follow the stage of this encouraging drug and post when I know more.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment